Skip to content
ContentLora

    Tip: press / anywhere to search.

    product

    LOY-002 (Loyal's senior dog lifespan drug)

    Also known as LOY-002, Loyal senior dog pill

    LOY-002 is an experimental daily pill from the company Loyal, intended to extend the lifespan of dogs aged 10 and older by improving insulin sensitivity.[1] As of October 2026 the FDA has accepted its effectiveness and safety sections, but manufacturing review remains before conditional approval can be considered, and approval is not guaranteed.[2][3][4]

    Editor reviewedStrict sourcingUpdated Aging and longevity biologyLife sciencesHealth and medicine
    Key facts

    What LOY-002 is

    LOY-002 is a once-daily pill developed by the company Loyal for senior dogs, aged 10 or older and weighing at least 14 pounds. Loyal says it is intended to preserve quality of life and extend lifespan by improving insulin sensitivity and lowering insulin levels.[1] It is a veterinary product, regulated by the FDA’s Center for Veterinary Medicine.[3]

    Dogs are a useful test case for aging drugs because they share the human environment and have shorter lives.[5]

    Regulatory path

    LOY-002 is following a conditional approval route with three major requirements.[4]

    • Effectiveness (RXE). In February 2025 the FDA accepted the reasonable expectation of effectiveness section. A Loyal executive described this as meaning the drug has a reasonable expectation of extending a dog’s life.[2]
    • Safety (TAS). In January 2026 the FDA accepted the target animal safety section.[3] Loyal says this was part of an Expanded Conditional Approval (XCA) application, and frames the drug as addressing the metabolic dysfunction that all dogs develop with age.[6]
    • Manufacturing. This section must still be accepted before conditional approval can be considered. As of October 2026, Loyal’s website says two of three major requirements are complete and that FDA approval is not guaranteed.[4]

    Acceptance of the effectiveness section is based on preliminary data. It is not proof that the drug extends life.[2]

    The STAY study

    Loyal’s STAY study completed enrolment in July 2025 with about 1,300 dogs at 70 US veterinary clinics.[7] As of October 2026 Loyal’s website gives the exact figure as 1,317 dogs.[8] It is a separate effort from TRIAD, the Dog Aging Project’s randomized trial of rapamycin in pet dogs, which plans to enrol 580 dogs and uses survival time as its primary outcome.[9][10] STAY is roughly twice that size.[8][10]

    Loyal’s other programs

    LOY-002 is one of three drug programs Loyal lists as in development.[8] The other two target large and giant-breed dogs:

    • LOY-001, an injectable drug, received RXE acceptance in November 2023. Loyal describes it as the first drug to achieve an RXE acceptance for lifespan extension in any species.[11]
    • LOY-003, a once-daily tablet, received RXE acceptance on 16 September 2026, according to Loyal. Like LOY-001, it is designed to lower growth hormone and IGF-1, hormones that drive growth and are linked to shorter lifespans in big dogs.[12]

    The growth and insulin signals these drugs act on are part of nutrient sensing, and deregulated nutrient sensing is one of the twelve hallmarks of aging.[13] All three RXE acceptances rest on preliminary evidence, not completed lifespan trials.[2]

    Why it matters

    In humans, the FDA does not recognize aging as a disease and no regulatory framework exists for approving aging-targeted therapies, so they are developed through disease-specific pipelines.[14] By contrast, in this veterinary pathway the FDA has already accepted an effectiveness section framed around lifespan.[2] Whether LOY-002 actually extends dogs’ lives will depend on the STAY results.[7] For the human drugs that act on similar metabolic pathways, see how GLP-1 drugs work and the tame-trial of metformin.

    Questions readers ask

    Is LOY-002 approved?

    Not as of October 2026. Loyal says two of three major requirements for FDA conditional approval are complete and approval is not guaranteed.[4]

    What did the FDA accept in 2025?

    The reasonable expectation of effectiveness (RXE) section, which Loyal describes as meaning the drug has a reasonable expectation of extending a dog's life.[2]

    How large is the main study?

    Loyal's STAY study enrolled about 1,300 dogs at 70 US veterinary clinics, completing enrolment in July 2025.[7]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      LOY-002 targets dogs aged 10 or older weighing at least 14 pounds and is intended to work by improving insulin sensitivity and lowering insulin levels. confirmedas of 2026-10-10

    2. [2]

      In February 2025 the FDA's Center for Veterinary Medicine accepted the reasonable expectation of effectiveness (RXE) section for Loyal's LOY-002, a daily pill intended to extend lifespan in senior dogs. confirmedas of 2025-02-26

    3. [3]

      In January 2026 the FDA accepted the target animal safety (TAS) technical section of LOY-002's conditional approval application. confirmedas of 2026-01-13

    4. [4]

      The manufacturing section must still be accepted before LOY-002 can be considered for conditional approval; as of October 2026 Loyal says two of three major requirements are complete and approval is not guaranteed. confirmedas of 2026-10-10

    5. [5]

      Companion dogs are considered a useful aging model because they share the human environment and have shorter life expectancy than people, allowing faster tests of interventions. confirmedas of 2025-02-14

    6. [6]

      Loyal says the FDA accepted the target animal safety section of its Expanded Conditional Approval (XCA) application for LOY-002, and describes the drug as aiming to address the metabolic dysfunction that all dogs experience as they age. confirmedas of 2026-01-13

    7. [7]

      Loyal's STAY study of LOY-002 completed enrolment of about 1,300 dogs at 70 US veterinary clinics in July 2025. confirmedas of 2026-01-13

    8. [8]

      As of October 2026 Loyal's website lists 1,317 dogs enrolled in the STAY trial at 70 veterinary practices and three drug programs in development. confirmedas of 2026-10-10

    9. [9]

      TRIAD is a double-masked, randomized, placebo-controlled multicenter trial testing whether rapamycin extends lifespan and improves healthspan in healthy middle-aged companion dogs from the Dog Aging Project. confirmedas of 2025-02-14

    10. [10]

      TRIAD plans to enrol and randomize 580 dogs, with survival time from randomization as its primary outcome. confirmedas of 2025-02-14

    11. [11]

      LOY-001, Loyal's injectable drug for large and giant-breed dogs, received RXE acceptance in November 2023, which Loyal describes as the first RXE acceptance for lifespan extension in any species. confirmedas of 2026-09-16

    12. [12]

      On 16 September 2026 Loyal said the FDA had accepted the reasonable expectation of effectiveness (RXE) for LOY-003, a once-daily tablet meant to extend the lifespan of large and giant-breed dogs by lowering growth hormone and IGF-1; Loyal says this is its third RXE, after LOY-001 and LOY-002. reportedas of 2026-09-16

    13. [13]

      A 2023 update in Cell expanded the list to twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation and dysbiosis. confirmedas of 2026-10-10

    14. [14]

      Papers published in 2025 in peer-reviewed journals state that the FDA does not recognize aging as a disease and that no regulatory framework exists for developing or approving therapies that target aging, so such therapies are developed through disease-specific pipelines. confirmedas of 2025-08-04

    Revision history (2)
    1. Page created.
    2. Refresh: added LOY-003's September 2026 RXE, LOY-001, the 1,317-dog STAY figure and a comparison with TRIAD; made company and news excerpts verbatim.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "LOY-002 (Loyal's senior dog lifespan drug)." ContentLora, updated Oct 10, 2026. https://contentlora.com/wiki/loy-002

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    Connections
    Rapamycin and mTOR … Companion-dog trial along…TAME trial Regulatory contrast with
    ☰ Contents